Randomized clinical trial intervention to treat chronic pain among persons maintained on methadone for opioid use disorder

Active Project Grant Awarded Last action

Award ID
R01DA056045
Recipient
Awarding agency
Obligated
$6,977,238

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 75% complete
Originally
Place of performance
Baltimore, MD 21201, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This R01 application follows a successfully completed R34 project and addresses our overarching goal of optimizing methadone dosing as a method for managing comorbid chronic pain and opioid use disorder (OUD) among persons receiving methadone for the treatment of OUD. Up to 62% of persons maintained on methadone for OUD experience clinically significant pain, versus 31% in the general population. Pain in MMP is associated with poor OUD treatment outcomes and severe distress. No effective treatment for comorbid pain and OUD currently exists; though preclinical and human data suggest divided methadone dosing may be a more optimal strategy for managing pain than once daily dosing, this has never been empirically examined. This study will evaluate an intervention for comorbid chronic pain among MMP using a double-blind, randomized, placebo-controlled comparison of once versus twice daily methadone dosing. This project is strongly supported by our recent successful completion of an R34, which demonstrated strong feasibility and acceptability of an electronic, autonomous, cellular-enabled commercially available pillbox (MEDMINDER) to manage methadone take-home dosing. Participants in that study indicated they would use the pillbox again (86%) and recommend IT to others (95%), local clinics adopted the MEDMINDER box into their routine take-home management operations, and preliminary within-person data showed clear and orderly pain reductions during the twice VS. Once dosing periods. Patients from two methadone clinics will be enrolled into a phase II between-group study and randomized to once versus twice-daily methadone dosing for 12-weeks. Methadone will be dispensed via the same electronic pillbox used in the R34. Primary outcomes are weekly assessments of pain and OUD outcomes, ecological momentary assessment of pain before and after dosing, and point-prevalence measures of laboratory-induced pain to explore mechanism of effects. We will assess the following aims: (primary 1) determine impact of methadone dose interval (once VS. Twice) on pain severity, (primary 2) determine impact of methadone dose interval (once VS. Twice) on pain-related function, (primary 3) determine impact of methadone dose interval (once VS. Twice) on OUD-related metrics, and (secondary 1) determine impact of methadone dosing interval on response to laboratory-induced pain using quantitative sensory testing. We expect participants assigned to twice daily dosing will show decreases in pain severity, improved pain-related function, and no change or improvements in OUD-related outcomes relative to persons receiving standard-of-care once daily dosing. If effective, this approach could transform the care of MMP with pain because IT would be feasible to implement within the operational structure of a methadone clinic and would impose low provider burden. Results could provide a high magnitude treatment for the substantial number of MMP who experience daily pain with no reliable form of treatment.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $659,647
Amendment $659,647
Amendment $659,647
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $692,181
Amendment $692,181
Amendment $692,181
Amendment $692,181
Amendment $0
Amendment $0
Amendment $0
Amendment $743,191
Amendment $743,191
Original award $743,191
Show all 23

Subawards

Subrecipient Amount Awarded
The Johns Hopkins University Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder. $134,748
Rector & Visitors Of The University Of Virginia Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid use disorder $66,057
Friends Research Institute, Inc. $66,056
Institutes For Behavior Resources, Inc. $133,548

Quick answers

Who received award R01DA056045?

R01DA056045 was awarded to University Of Maryland, Baltimore by National Institute on Drug Abuse (National Institutes of Health) on June 1, 2022.

How much is award R01DA056045 worth?

$6,977,238 has been obligated on R01DA056045.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login